Phaseline

Companies › BeOne Medicines

BeOne Medicines: clinical trials, targets and expected readouts

21 active drug programs in 340 registered trials: 229 Phase 2, 68 Phase 1, 40 Phase 3, 3 Phase 4; Oncology, Other, Genitourinary, Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sonrotoclax Tablet for Oral Suspension (BGB-11417)
Bcl-2 inhibitor
BCL2Phase 3Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia; CLL; Waldenstrom Macroglobulinemia …Nov 2026
Zanubrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3B-cell Malignancies; Relapsed/Refractory Follicular Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Non-Hodgkin Lymphoma …Nov 2026
BGB-43395
Cyclin-dependent kinase 4 inhibitor
CDK4Phase 3HR+/HER2- Breast Cancer; Healthy Adult Participants; Hormone-receptor-positive Breast Cancer; Advanced Solid TumorNov 2026
Tacabrutideg (BGB-16673)
BTK inhibitor
BTKPhase 3Chronic Lymphocytic Leukemia; CLL; Chronic Spontaneous Urticaria; B-cell MalignancyNov 2026
Tislelizumab (A317)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3B-cell Malignancies; Metastatic Gastric Adenocarcinoma; Advanced Esophageal Squamous Cell Carcinoma; Advanced Unresectable Gastric Adenocarcinoma …Dec 2026
BG-C137
anti-FGFR2b antibody-drug conjugate
FGFR2Phase 1Advanced Solid TumorDec 2026
BGB-B2033
Anti-glypican-3 (GPC3) antibody
GPC3Phase 1Metastatic Hepatocellular CarcinomaMar 2027
BGB-58067
MTAP inhibitor
MTAPPhase 1Healthy Volunteers; Advanced Solid TumorJul 2027
BGB-21447
Bcl-2 inhibitor
BCL2Phase 1Hormone-receptor-positive Breast CancerJul 2027
BG-C9074–Phase 1Advanced Solid TumorSep 2027
BG-C0902
Bispecific anti-EGFR and anti-MET antibody-drug conjugate with topoisomerase 1 inhibitor p
EGFR, METPhase 1Solid TumorsNov 2027
BGB-B455
anti-CLDN6 antibody-drug conjugate
CLDN6Phase 1Advanced Solid TumorApr 2028
BG-C477–Phase 1Advanced Solid TumorsJul 2028
BG-A3004–Phase 1Skin DiseasesAug 2028
BG-89894–Phase 1Advanced Solid TumorAug 2028
BG-75202
KAT6A/B inhibitor
KAT6A, KAT6BPhase 1Myeloid Malignancy; Breast CancerSep 2028
BG-85738
RAS inhibitor (likely KRAS inhibitor)
–Phase 1RAS MutationSep 2028
BG-T187–Phase 1Advanced Solid TumorSep 2028
BG-75098–Phase 1Advanced Solid TumorNov 2028
BGB-26808
Unclear - mechanism not specified in registry
–Phase 1Advanced Solid TumorFeb 2029
BG-C0979–Phase 1Advanced Solid TumorApr 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04460248ZanubrutinibPhase 2Diffuse Large B Cell LymphomaOncologyFeb 2022
NCT05199909ZanubrutinibPhase 2Antiphospholipid SyndromeHematologyDec 2023
NCT05972655Tislelizumab (A317)Phase 2Low Rectal CancerOncologyAug 2024
NCT05319639Tislelizumab (A317)Phase 1Gastric Cancer Stage IVOncologyOct 2024
NCT05586061Tislelizumab (A317)Phase 2HER2-positive Gastric CancerOncologyDec 2024
NCT06239532Tislelizumab (A317)Phase 2Intrahepatic CholangiocarcinomaOncologyDec 2024
NCT05464433Tislelizumab (A317)Phase 1Extranodal Natural Killer T Cell LymphomaOncologyApr 2025
NCT04954781Tislelizumab (A317)Phase 2Intrahepatic CholangiocarcinomaOncologyJul 2025
NCT05758389Tislelizumab (A317)Phase 2Head and Neck TumorsOncologyAug 2025
NCT05984602Tislelizumab (A317)Phase 1Pancreatic CancerOncologySep 2025
NCT05520619Tislelizumab (A317)Phase 2Esophageal Squamous Cell CarcinomaOncologyNov 2025
NCT05557578Tislelizumab (A317)Phase 2Intrahepatic CholangiocarcinomaOncologyNov 2025
NCT06032845Tislelizumab (A317)Phase 2Solid Tumor, AdultOncologyDec 2025
NCT05920863Tislelizumab (A317)Phase 2Hepatocellular CarcinomaOncologyDec 2025
NCT05214391ZanubrutinibPhase 2Immune ThrombocytopeniaHematologyDec 2025
NCT06916494Tislelizumab (A317)Phase 1Muscle Invasive Bladder CancerOncologyJan 2026
NCT06132698Tislelizumab (A317)Phase 2NSCLC Associated With Leptomeningeal MetastasesOncologyMay 2026
NCT06364956Tislelizumab (A317)Phase 1Bladder CancerOncologyJun 2026
NCT06157996Tislelizumab (A317)Phase 2Gastric CancerOncologyAug 2026
NCT05057845Tislelizumab (A317)Phase 2Advanced Hepatocellular CarcinomaOncologySep 2026
NCT07628881Sonrotoclax Tablet for Oral Suspension (BGB-11417)Phase 1Healthy VolunteersOtherSep 2026
NCT07590102BGB-58067Phase 1Healthy VolunteersOtherOct 2026
NCT06637501ZanubrutinibPhase 2Chronic Lymphocytic LeukemiaOncologyNov 2026
NCT06637501Sonrotoclax Tablet for Oral Suspension (BGB-11417)Phase 2Chronic Lymphocytic LeukemiaOncologyNov 2026
NCT04973605Sonrotoclax Tablet for Oral Suspension (BGB-11417)Phase 1Relapsed/Refractory Multiple MyelomaOncologyNov 2026
NCT06695013Tislelizumab (A317)Phase 2B-NHLOncologyNov 2026
NCT06695013ZanubrutinibPhase 2B-NHLOncologyNov 2026
NCT07820891BGB-43395Phase 1Healthy Adult ParticipantsOtherNov 2026
NCT06124378Tislelizumab (A317)Phase 2Colonic NeoplasmsOncologyNov 2026
NCT06749886Tislelizumab (A317)Phase 2Lung CancerOncologyNov 2026
NCT07005713Tacabrutideg (BGB-16673)Phase 1Chronic Spontaneous UrticariaImmunologyNov 2026
NCT04615143Tislelizumab (A317)Phase 2Recurrent Hepatocellular CarcinomaOncologyDec 2026
NCT06647680Tislelizumab (A317)Phase 2Rectal Cancer PatientsOncologyDec 2026
NCT06312982Tislelizumab (A317)Phase 2Locally Advanced Rectal CarcinomaOncologyDec 2026
NCT06561347ZanubrutinibPhase 2Waldenstrom MacroglobulinemiaOncologyDec 2026
NCT06547944ZanubrutinibPhase 1Chronic Lymphocytic LeukemiaOncologyDec 2026
NCT06177301Tislelizumab (A317)Phase 3Nasopharyngeal CarcinomaOncologyDec 2026
NCT06838910Tislelizumab (A317)Phase 2Thymic CarcinomaOncologyDec 2026
NCT07000617Tislelizumab (A317)Phase 2NK/T Cell LymphomaOncologyDec 2026
NCT07512674Tislelizumab (A317)Phase 2Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal MetastasisOncologyDec 2026
NCT05531123Tislelizumab (A317)Phase 2Bladder CancerOncologyDec 2026
NCT06538896Tislelizumab (A317)Phase 2Triple-negative Breast CancerOncologyDec 2026
NCT05659628Tislelizumab (A317)Phase 1Diffuse Large B-cell LymphomaOncologyDec 2026
NCT06005870ZanubrutinibPhase 2Diffuse Large B Cell LymphomaOncologyDec 2026
NCT04624958ZanubrutinibPhase 2Mantle Cell LymphomaOncologyDec 2026
NCT04850495ZanubrutinibPhase 1Diffuse Large B-Cell LymphomaOncologyDec 2026
NCT05253118Tislelizumab (A317)Phase 2DLBCLOncologyDec 2026
NCT05917431Tislelizumab (A317)Phase 2Unresectable Hepatocellular CarcinomaOncologyDec 2026
NCT06446726Tislelizumab (A317)Phase 2Esophageal Squamous Cell CarcinomaOncologyDec 2026
NCT06211790Tislelizumab (A317)Phase 2Kidney CancerOncologyDec 2026
NCT05912816Tislelizumab (A317)Phase 2Upper Urinary Tract Urothelial CarcinomaOncologyDec 2026
NCT06664021Tislelizumab (A317)Phase 2Intrahepatic CholangiocarcinomaOncologyDec 2026
NCT06356597Tislelizumab (A317)Phase 2Colorectal CancerOncologyDec 2026
NCT07126119Tislelizumab (A317)Phase 2Upper Tract Urothelial CarcinomaOncologyDec 2026
NCT07125547Tislelizumab (A317)Phase 2Ureteral CancerOncologyDec 2026
NCT05837806Tislelizumab (A317)Phase 2Neoadjuvant ImmunotherapyOtherDec 2026
NCT07233252Tislelizumab (A317)Phase 2Renal Pelvic CarcinomaGenitourinaryDec 2026
NCT06471738ZanubrutinibPhase 2Ann Arbor Stage II Follicular LymphomaOncologyDec 2026
NCT06625593BG-C137Phase 1Advanced Solid TumorOncologyDec 2026
NCT04170283Tislelizumab (A317)Phase 3B-cell MalignanciesOncologyDec 2026

The 60 nearest readouts of 340 trials; the rest in the app.

From the company's SEC filings

Cash of $5.8bn on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

BTK (2) BCL2 (2) CDK4 (1) MTAP (1) FGFR2 (1) PDCD1 (1) CLDN6 (1) KAT6A (1) KAT6B (1) GPC3 (1) EGFR (1) MET (1)

Companies with the same targets

AstraZeneca Akeso Johnson & Johnson (Janssen) Pfizer Ono Pharmaceutical Eli Lilly Novartis AbbVie Ascentage Pharma Group Bristol-Myers Squibb

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.